Satellos Bioscience (MSLE) vs OnKure Therapeutics (OKUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
OnKure Therapeutics (OKUR) has outperformed Satellos Bioscience (MSLE) over the past year, gaining 4.7% versus a loss of 5.3%. Over five years, MSLE leads with a -58.5% price change compared with -96.2% for OKUR. Satellos Bioscience is the larger company by market cap ($120.5 million vs $111.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MSLE | OKUR |
|---|---|---|
| Share price | $5.68 | $2.70 |
| Market cap | $120.51M | $111.21M |
| 1-day change | -2.07% | -2.17% |
| YTD return | -3.40% | -6.90% |
| 1-year return | -5.33% | +4.65% |
| 5-year return | -58.48% | -96.16% |
| EPS (TTM) | $-2.12 | $-2.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-24.87M | $-59.52M |
| 52-week high | $13.40 | $5.38 |
| 52-week low | $5.44 | $2.01 |
| Distance from 52-week high | -57.60% | -49.81% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +325.53% | +464.81% |
| Average volume | 51.19K | 335.78K |
| Shares outstanding | 21.22M | 40.50M |
| Employees | 18 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Satellos Bioscience
MSLE stock →Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.
Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees
About OnKure Therapeutics
OKUR stock →OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 45 employees
MSLE vs OKUR FAQ
Which is bigger, Satellos Bioscience or OnKure Therapeutics?
Satellos Bioscience (MSLE) is larger, with a market capitalization of $120.51M compared with $111.21M for OnKure Therapeutics (OKUR).
Which stock has performed better over the past year, MSLE or OKUR?
OKUR returned +4.65% over the past 12 months, compared with -5.33% for MSLE (price return, excluding dividends). Past performance does not predict future results.
Are Satellos Bioscience and OnKure Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.